Clearwater Paper (CLW) Q3 2026 Earnings Call Transcript

Clearwater Paper reported Q3 2026 net sales of $385 million, down 4% year over year, and adjusted EBITDA of $24.4 million within its $20 million–$30 million guidance range; the $2 million continuing-operations loss included $17.5 million in insurance proceeds. Augusta mill disruptions and Middle East-related costs weighed on results, including $12 million of conflict-related costs in Q3 and a projected $28 million–$32 million impact for full-year 2026; Q4 adjusted EBITDA guidance is $10 million–$20 million. The company refinanced with a $275 million term loan and a $200 million revolver, extending maturities to 2031, while planning a $3 million–$5 million CUK launch investment and an Augusta maintenance outage costing $12 million–$15 million in January 2027.

Analysis

CLW’s key issue is conversion of announced price increases into durable cash earnings—not the headline annualized benefit. The company’s claimed >$70 million annual benefit is a run-rate estimate; realization depends on index resets, customer contract lags, and sustaining volumes while imports remain resilient. That makes the Q4 EBITDA step-down important: seasonal costs and Augusta reliability problems arrive before the pricing benefit is fully visible.

Cash generation also looks better than underlying operations. Final insurance proceeds, tax refunds, and planned working-capital releases support near-term deleveraging, but are not repeatable earnings. Against that, the roughly 8.25% effective rate and ~$25 million go-forward annual interest burden leave less room for execution errors. Refinancing reduces near-term maturity risk, but does not remove the operating/capex risk: Augusta outages and additional work could absorb cash into 2027. The CFO’s imminent departure adds some execution risk during this transition.

The CUK plan is a sensible low-capital test, but its value depends on customer qualification, realized contribution margins, and the SBS production displaced on the swing machine. Management’s demand-capture target is not evidence of orders. The contrarian risk is that improving industry utilization and pricing may be partly offset by persistent imports, input-cost inflation, and mill underperformance; conversely, if Augusta normalizes, the earnings response could be amplified by pricing. Near-term reaction is likely dominated by Q4 guidance and reliability; the 1–3 month test is price realization and production recovery; the 6–18 month test is outage execution and CUK economics.

Key Decisions for Investors

• Avoid chasing the pricing narrative; keep CLW on watch rather than initiate an outright long before evidence that price increases are reaching reported results. Reassess after the next quarterly report for realized price/ton, shipment trends, and EBITDA excluding insurance proceeds.
• Treat Augusta reliability as the primary near-term risk trigger. Turn more constructive only if production recovers toward capability and the January outage remains within the stated $12–15 million cost range; renewed failures, further outage slippage, or materially higher required capital would falsify the recovery case.
• Track cash conversion separately from reported deleveraging: verify working-capital release, capex, and recurring free cash flow after insurance and tax benefits. If interest expense approaches the stated ~$25 million while free cash flow remains dependent on one-offs, avoid adding exposure.
• Treat CUK as an option, not a valuation premise. Upgrade the thesis only after customer trials convert to repeat orders and management demonstrates attractive contribution without materially sacrificing SBS economics; monitor CFO succession and any guidance change alongside that evidence.